Oncology
Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial
August 10, 2023Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology
Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …
Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology
August 10, 2023Business Services Glympse Bio, Oncology, Sunbird Bio, merger, oncology
Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to accelerate the development of both …
FDA grants clearance to next phase of Ascentage Pharma’s clinical trial for CLL/SLL treatment
August 8, 2023Research and Development Ascentage Pharma, CLL/SLL, FDA, Oncology, clinical trial
Ascentage Pharma has announced that the US Food and Drug Administration (FDA) has granted clearance for the phase 3 study …
Astex expands collaboration with MSD
August 8, 2023Business Services Astex pharmaceuticals, Merck, Oncology, collaboration, small molecules
Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with MSD (known as Merck in the US), …
Targeted chemotherapy to kill all solid tumours developed in preclinical research
August 3, 2023Research and Development Cancer, Oncology, chemotherapy, pharmaceutical, tumour
Researchers from the City of Hope organisation in the US have released a study confirming the development of AOH1996, a …
FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment
August 3, 2023Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho
Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …
FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma
August 3, 2023Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma
ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
GSK’s Jemperli approved for treatment of endometrial cancer
August 1, 2023Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer
GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
Hummingbird Bioscience initiates phase 1b trials for sqNSCLC
July 27, 2023Research and Development Hummingbird Bioscience, Omico, Oncology, clinical trials, sqNSCLC
Hummingbird Bioscience has announced the initiation of two phase 1b clinical trials taking place in Australia. The trials will evaluate …
BioIVT acquires PrecisionMed for neurology and oncology research
July 21, 2023Sales and Marketing Neurology, Oncology, neurology, oncology
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …
EMA accepts Astellas’ MAA for Zolbetuximab
July 14, 2023Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …
CellCentric announces $25m investment from Pfizer
July 12, 2023Business Services Cancer, CellCentric, Oncology, Pfizer, collaboration, investment
UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance further development of inobrodib, its …
ADC Therapeutics puts clinical trial enrollment on hold following patient deaths
July 12, 2023Medical Communications ADC Therapeutics, DLBCL, Oncology, clinical trial
ADC Therapeutics has announced a voluntary pause in the enrollment of patients for its phase 2 LOTIS-9 clinical trial which …
Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial
July 11, 2023Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma
Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …
Latest content
FibroFind appoints Lee Borthwick as CEO
